Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $10.5352W HIGH $11.95
Volume
204.51 K
Value Traded
2.51 K
Short % Float
0.01%
Days to Cover
1.0
-37.23%Week
-36.03%1 Month
-36.09%3 Month
-33.85%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
22.43 M
EPS (TTM)
0.31
P/E Ratio
24.74
Ent. Value
20.34 M
Total Shares
4.15 M
Float Shares
3.68 M
Insiders
11.47%
Institutions
44.17%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BKHA Catalyst Timeline
Dated clinical, regulatory and corporate events for Black Hawk Acquisition Corporation Class A Ordinary Shares
Past FDA Catalysts and PDUFA Decisions
How BKHA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every BKHA program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BKHA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BKHA for Q2 2026. | ||||
BKHA Institutional Ownership Trends
BKHA Short Interest
Shares sold short, counted twice a month.
0.01%
Short % of Float
of tradable shares sold short
501
Shares Sold Short
+845.3% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
16.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BKHA ranks across every disease it competes in
Competitive Position is a premium feature
See how BKHA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBKHA News
-BKHA
Mar 17, 2026Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer Blackhawk, Calif.
Vesicor Therapeutics has appointed Dr. Michael Tolentino, M.D., as its new Chief Executive Officer, effective March 17, 2026. Dr. Tolentino, an accomplished figure in the biotech industry, succeeds the company's founder Luo Feng, who will now serve as Chief Scientific Officer. The company is focusing on advancing its p53-based cancer therapeutics and is currently pursuing a proposed merger with Blackhawk Acquisition Corporation. Dr. Tolentino expressed his commitment to build upon the company’s technology and accelerate its development towards an IND submission in 2027.
Read more →-BKHA
Jul 7, 2025Black Hawk Acquisition Corporation Amends Its Definitive Proxy Statement
Black Hawk Acquisition Corporation has filed a supplement to its definitive proxy statement to amend the Trust Amendment Proposal. The amendment changes the deposit requirement for extensions related to initial business combinations from an amount based on outstanding shares to a fixed amount of $150,000 per month. This update aims to eliminate ambiguity regarding deposit amounts and reinforce the company's obligations. The press release indicates there are risks associated with forward-looking statements.
Read more →-BKHA
Apr 28, 2025Vesicor Therapeutics, Inc. and Black Hawk Acquisition Corporation Enter into a Business Combination Agreement to Create a Biotechnology Company Advancing p53-based Cancer Therapeutics Delivered Via Microvesicles
Vesicor Therapeutics, Inc. has entered into a Business Combination Agreement with Black Hawk Acquisition Corporation to create a biotechnology company focused on p53-based cancer therapeutics. This transaction will pave the way for Vesicor to become a public company and to access capital for advancing its drug candidate, ecm-RV/p53, which is aimed at treating various forms of cancer. The deal, valued at $70 million, is expected to close by the fourth quarter of 2025, subject to regulatory and shareholder approvals. Vesicor plans to initiate preclinical testing and begin clinical trials in the near future.
Read more →-BKHA
Apr 23, 2024Black Hawk Acquisition Corporation Welcomes Mr. Jonathan Ginsberg to Board Danville, CA.
Black Hawk Acquisition Corporation has appointed Mr. Jonathan Ginsberg as a director and Chief Operating Officer. Ginsberg, age 33, brings valuable experience from international trade and education, previously serving as President of BEEC Inc. His appointment is seen as a strategic move to enhance the company’s leadership without any disclosed conflicts with current board members.
Read more →-BKHA
Mar 22, 2024BLACK HAWK ACQUISITION CORPORATION INDEX TO FINANCIAL STATEMENT Page Report of Independent Registered Public Accounting Firm (PCAOB ID: 206) F-2 Financial Statement (Audited): Balance Sheet as of
Black Hawk Acquisition Corporation has released its independent auditor's report and financial statements as of March 22, 2024. The audit indicates that the financial position presents fairly, however, there are significant concerns regarding the company's ability to operate as a going concern. The company is dependent on successfully completing a business combination within a certain timeframe, failing which it will have to liquidate. Financial highlights include total assets of approximately $70.3 million, with a shareholder deficit of about $1.8 million.
Read more →-BKHA
Mar 20, 2024Black Hawk Acquisition Corporation Announces Pricing of $69,000,000 Upsized Initial Public Offering Danville, CA.
Black Hawk Acquisition Corporation announced the pricing of its initial public offering at $69 million, consisting of 6,900,000 units priced at $10.00 each. The units are set to trade on the NASDAQ under the ticker symbol "BKHAU" beginning March 21, 2024. The IPO includes options for underwriters to purchase additional units, with the transaction expected to close by March 22, 2024, pending customary conditions. This offering marks a significant step for the company as it seeks to pursue business combinations.
Read more →About Black Hawk Acquisition Corporation Class A Ordinary Shares
Headquarters4125 BLACKHAWK PLAZA CIRCLE, DANVILLE, CA, 94506
BIOPHARMAWATCH ELITE PLUS
Trade the next BKHA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime